Complete financial analysis of Orchard Therapeutics plc (ORTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orchard Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- First Bancshares Inc. (Bellevue, OH) (FIBH) Income Statement Analysis – Financial Results
- Man Wah Holdings Limited (MAWHY) Income Statement Analysis – Financial Results
- Schibsted ASA (SCHB.OL) Income Statement Analysis – Financial Results
- Kiu Hung International Holdings Limited (0381.HK) Income Statement Analysis – Financial Results
- FSN E-Commerce Ventures Limited (NYKAA.BO) Income Statement Analysis – Financial Results
Orchard Therapeutics plc (ORTX)
About Orchard Therapeutics plc
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.99M | 483.00K | 2.60M | 2.51M | 2.08M | 0.00 | 0.00 |
| Cost of Revenue | 2.43M | 226.00K | 857.00K | 805.00K | 422.00K | 0.00 | 0.00 |
| Gross Profit | 4.55M | 257.00K | 1.74M | 1.71M | 1.65M | 0.00 | 0.00 |
| Gross Profit Ratio | 65.17% | 53.21% | 66.97% | 67.97% | 79.67% | 0.00% | 0.00% |
| Research & Development | 25.55M | 23.35M | 93.73M | 117.36M | 205.32M | 32.53M | 16.21M |
| General & Administrative | 44.66M | 49.65M | 56.89M | 49.16M | 0.00 | 5.99M | 3.00M |
| Selling & Marketing | 4.14M | 5.26M | 8.09M | 8.06M | 0.00 | 0.00 | 0.00 |
| SG&A | 10.60M | 13.55M | 64.99M | 57.22M | 31.37M | 5.99M | 3.00M |
| Other Expenses | 22.66M | 811.00K | 3.41M | 1.39M | 5.51M | -1.18M | 138.00K |
| Operating Expenses | 36.15M | 36.90M | 158.72M | 174.58M | 236.69M | 38.51M | 19.20M |
| Cost & Expenses | 38.58M | 36.90M | 159.57M | 175.39M | 237.11M | 38.51M | 19.20M |
| Interest Income | 857.00K | 63.00K | 3.19M | 7.36M | 0.00 | 0.00 | 3.00K |
| Interest Expense | 933.00K | 683.00K | 2.33M | 1.54M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 23.51M | 874.00K | 8.60M | 8.75M | 1.20M | 302.00K | 6.00K |
| EBITDA | -8.08M | -35.54M | -148.38M | -164.12M | -235.03M | -38.21M | -19.20M |
| EBITDA Ratio | -115.65% | -7,358.39% | -5,717.84% | -6,531.00% | -11,321.34% | 0.00% | 0.00% |
| Operating Income | -31.59M | -36.42M | -156.98M | -172.87M | -235.03M | -38.51M | -19.20M |
| Operating Income Ratio | -452.22% | -7,539.34% | -6,049.25% | -6,879.15% | -11,321.34% | 0.00% | 0.00% |
| Total Other Income/Expenses | -25.95M | -3.32M | 4.27M | 7.21M | 5.51M | -1.18M | 138.00K |
| Income Before Tax | -9.01M | -36.22M | -152.71M | -165.66M | -229.53M | -39.69M | -19.07M |
| Income Before Tax Ratio | -129.00% | -7,499.79% | -5,884.78% | -6,592.20% | -11,056.12% | 0.00% | 0.00% |
| Income Tax Expense | -1.13M | 125.00K | -731.00K | -2.24M | 970.00K | 53.00K | 20.00K |
| Net Income | -7.88M | -36.35M | -151.98M | -163.42M | -230.50M | -39.74M | -19.09M |
| Net Income Ratio | -112.84% | -7,525.67% | -5,856.61% | -6,503.06% | -11,102.84% | 0.00% | 0.00% |
| EPS | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| Weighted Avg Shares Out | 12.80M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
| Weighted Avg Shares Out (Dil) | 12.82M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
Why Infinity Pharma, Meridian Bio, More Biotech Stocks Are Moving Today
Orchard Therapeutics Announces $150 Million Strategic Financing
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD
Orchard Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)
Bet on Rising P/E Investing With These Top 5 Stocks
Orchard Therapeutics Reports OTL-201 Initial Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA)
Orchard Therapeutics Announces FDA Clearance of IND Application for OTL-200 for Metachromatic Leukodystrophy (MLD)
Source: https://incomestatements.info
Category: Stock Reports